Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 1
2001 1
2003 3
2004 1
2005 3
2006 2
2007 4
2008 3
2009 1
2010 3
2011 2
2013 1
2016 2
2018 6
2019 3
2020 4
2021 3
Text availability
Article attribute
Article type
Publication date

Search Results

38 results
Results by year
Filters applied: . Clear all
Page 1
IL10RA modulates crizotinib sensitivity in NPM1-ALK+ anaplastic large cell lymphoma.
Prokoph N, Probst NA, Lee LC, Monahan JM, Matthews JD, Liang HC, Bahnsen K, Montes-Mojarro IA, Karaca-Atabay E, Sharma GG, Malik V, Larose H, Forde SD, Ducray SP, Lobello C, Wang Q, Luan SL, Pospíšilová Š, Gambacorti-Passerini C, Burke GAA, Pervez S, Attarbaschi A, Janíková A, Pacquement H, Landman-Parker J, Lambilliotte A, Schleiermacher G, Klapper W, Jauch R, Woessmann W, Vassal G, Kenner L, Merkel O, Mologni L, Chiarle R, Brugières L, Geoerger B, Barbieri I, Turner SD. Prokoph N, et al. Among authors: sharma gg. Blood. 2020 Oct 1;136(14):1657-1669. doi: 10.1182/blood.2019003793. Blood. 2020. PMID: 32573700 Free PMC article.
Wiskott-Aldrich syndrome protein (WASP) is a tumor suppressor in T cell lymphoma.
Menotti M, Ambrogio C, Cheong TC, Pighi C, Mota I, Cassel SH, Compagno M, Wang Q, Dall'Olio R, Minero VG, Poggio T, Sharma GG, Patrucco E, Mastini C, Choudhari R, Pich A, Zamo A, Piva R, Giliani S, Mologni L, Collings CK, Kadoch C, Gambacorti-Passerini C, Notarangelo LD, Anton IM, Voena C, Chiarle R. Menotti M, et al. Among authors: sharma gg. Nat Med. 2019 Jan;25(1):130-140. doi: 10.1038/s41591-018-0262-9. Epub 2018 Dec 3. Nat Med. 2019. PMID: 30510251 Free PMC article.
We shall overcome (drug resistance) some day.
Sharma GG, Mologni L. Sharma GG, et al. Oncotarget. 2019 Jan 4;10(2):84-85. doi: 10.18632/oncotarget.26550. eCollection 2019 Jan 4. Oncotarget. 2019. PMID: 30719203 Free PMC article. No abstract available.
STAT3 and TP53 mutations associate with poor prognosis in anaplastic large cell lymphoma.
Lobello C, Tichy B, Bystry V, Radova L, Filip D, Mraz M, Montes-Mojarro IA, Prokoph N, Larose H, Liang HC, Sharma GG, Mologni L, Belada D, Kamaradova K, Fend F, Gambacorti-Passerini C, Merkel O, Turner SD, Janikova A, Pospisilova S. Lobello C, et al. Among authors: sharma gg. Leukemia. 2021 May;35(5):1500-1505. doi: 10.1038/s41375-020-01093-1. Epub 2020 Nov 27. Leukemia. 2021. PMID: 33247178 Free PMC article. No abstract available.
Phase two study of crizotinib in patients with anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma relapsed/refractory to chemotherapy.
Bossi E, Aroldi A, Brioschi FA, Steidl C, Baretta S, Renso R, Verga L, Fontana D, Sharma GG, Mologni L, Mussolin L, Piazza R, Gambacorti-Passerini C. Bossi E, et al. Among authors: sharma gg. Am J Hematol. 2020 Dec;95(12):E319-E321. doi: 10.1002/ajh.25967. Epub 2020 Sep 3. Am J Hematol. 2020. PMID: 32808682 Clinical Trial. No abstract available.
38 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page